HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc HCWB has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218.

  • The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS).
  • Cellular senescence is an essential mechanism for tumor suppression. However, chemotherapy & radiation, standard-of-care anti-cancer regimens, cause the accumulation of senescent cells both in tumor and normal tissue. 
  • Paradoxically, Cellular senescence protects non-dividing cancer cells by limiting the effect of chemotherapeutic drugs and radiation and contributes to chemoresistance, radiation resistance, disease relapse, and systemic side effects. 
  • In addition, the data exhibited that HCW9218 in combination chemotherapies can further augment the anti-cancer activities of therapeutic and immune-checkpoint antibodies against solid tumors. 
  • HCW Biologics received FDA clearance in October 2021 of an Investigational New Drug (IND) application for Phase 1b trial to evaluate HCW9218 in patients with advanced pancreatic cancer. 
  • Price Action: HCWB shares are up 11.1% at $2.30 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!